Clinical Trial

Effect of Trilaciclib in the Prevention of Myelosupression in Subjects With Limited-stage Small Cell Lung Cancer

Recruiting Phase 3
View on ClinicalTrials.gov →
Summary
The goal of this clinical trial is to compare the efficacy and safety of trilaciclib versus placebo in subjects with limited stage small cell lung cancer. The main question it aims to answer is: Does trilaciclib have a myeloprotective effect in subject with limited stage small cell lung cancer? Participants will be randomised to receive either trilaciclib or placebo.
Protocol Amendment History 1 change
critical Recruitment opened 2026-06-18
Trial Details
NCT Number NCT07473128
Lead Sponsor Pharmacosmos A/S
Conditions Limited Stage Small Cell Lung Cancer
Enrollment 120 participants
Start Date 2026-06-30
Primary Completion 2027-06 (estimated)
Study Completion 2027-06 (estimated)
Updated on ClinicalTrials.gov 2026-06-17